Evidence map›Paper›PMID 26943809›Full record

ArticlePloS one2016

Contrasting Roles of Islet Resident Immunoregulatory Macrophages and Dendritic Cells in Experimental Autoimmune Type 1 Diabetes.

Thomas B Thornley, Krishna A Agarwal, Periklis Kyriazis, Lingzhi Ma, Vaja Chipashvili, Jonathan E Aker, Sarantis Korniotis, Eva Csizmadia, Terry B Strom, Maria Koulmanda

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Thomas B ThornleyDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Krishna A AgarwalDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Periklis KyriazisDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Lingzhi MaDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Vaja ChipashviliDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Jonathan E AkerDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Sarantis KorniotisDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Eva CsizmadiaDepartment of Surgery, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Terry B StromDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.
Maria KoulmandaDepartment of Medicine, Harvard Medical School and the Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States of America.

Funding

RESEARCH TRAINING IN NEPHROLOGYT32DK007199 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI POLLAK, MARTIN R. · 1986 to 2022
$6.0M
Training Program in Angiogenesis &InflammationT32HL007893 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI DVORAK, HAROLD FISHER · 1998 to 2017
$5.5M
Role of Tim-4 in Regulating Type 1 DiabetesR01DK096138 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI KUCHROO, VIJAY K. · 2013 to 2016
$1.4M
NHLBI NIH HHS T32 HL007893NHLBI NIH HHS T32-HL007893NIDDK NIH HHS 5T32DK007199-37NIDDK NIH HHS R01 DK096138NIDDK NIH HHS R01-DK096138NIDDK NIH HHS T32 DK007199
6 · The paper itself

Abstract

The innate immune system critically shapes diabetogenic adaptive immunity during type 1 diabetes (T1D) pathogenesis. While the role of tissue-infiltrating monocyte-derived macrophages in T1D is well established, the role of their tissue-resident counterparts remains undefined. We now demonstrate that islet resident macrophages (IRMs) from non-autoimmune mice have an immunoregulatory phenotype and powerfully induce FoxP3+ Tregs in vitro. The immunoregulatory phenotype and function of IRMs is compromised by TLR4 activation in vitro. Moreover, as T1D approaches in NOD mice, the immunoregulatory phenotype of IRMs is diminished as is their relative abundance compared to immunostimulatory DCs. Our findings suggest that maintenance of IRM abundance and their immunoregulatory phenotype may constitute a novel therapeutic strategy to prevent and/or cure T1D.

Indexed as

AnimalsAntigens, CDDendritic CellsDiabetes Mellitus, Type 1FemaleForkhead Transcription FactorsIslets of LangerhansMacrophagesMice, Inbred C57BLMice, Inbred NODPhenotypeReal-Time Polymerase Chain ReactionT-Lymphocytes, RegulatoryToll-Like Receptor 4Antigens, CDForkhead Transcription FactorsFoxp3 protein, mouseToll-Like Receptor 4

Identifiers

PMID26943809
PMCPMC4778921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.